NOVO VENTURES CO-LEADS US$83M SERIES C FINANCING IN LAVA THERAPEUTICS

Novo Ventures, the ventures arm of Novo Holdings, today announced that it has co-led the oversubscribed $83 million (£71 million) Series C financing in LAVA Therapeutics (LAVA), a Dutch and US biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies. As a result of the financing, Nanna Lüneborg, Partner at Novo Ventures, will join the company’s board of directors.

Read more….

 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH